FDA punches BioMarin's 'golden ticket' for speedy drug review

Annabelle Bozarth started taking Vimizim, BioMarin Pharmaceutical's enzyme replacement therapy for MPS IVA, in a Phase III clinical trial.

http://ift.tt/1f5uEM9